Highbridge Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Highbridge Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,800	Closed	-$340K	–	1429
2017 Q4	$340K	Sell	6,800 -5,200	-43%	-$285K	0.01%	1155
2017 Q3	$603K	Buy	+12,000	New	+$629K	0.01%	819
2016 Q3	–	Sell	-9,400	Closed	-$219K	–	1482
2016 Q2	$219K	Buy	9,400 +3,500	+59%	+$113K	﹤0.01%	1204
2016 Q1	$239K	Buy	+5,900	New	+$240K	﹤0.01%	1266
2015 Q3	–	Sell	-20,800	Closed	-$1.2M	–	1686
2015 Q2	$1.2M	Sell	20,800 -1,300	-6%	-$82.7K	0.02%	670
2015 Q1	$1.41M	Buy	+22,100	New	+$1.5M	0.02%	639
2014 Q4	–	Sell	-10,400	Closed	-$404K	–	1283
2014 Q3	$404K	Sell	10,400 -1,400	-12%	-$49.6K	0.01%	905
2014 Q2	$406K	Buy	+11,800	New	+$372K	﹤0.01%	790
2013 Q3	–	Sell	-66,100	Closed	-$1.78M	–	1401
2013 Q2	$1.78M	Buy	+66,100	New	+$1.41M	0.02%	520

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's IONS Position: Q1 2020 in Review

Highbridge Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2020, closing a stake of 96,060 shares — an estimated $5.8M sold.

Highbridge Capital Management first reported a position in IONS in Q2 2015 and held it in 3 quarters. The position peaked at $5.8M in Q4 2019. 363 funds tracked by Wall St. Rank hold IONS as of Q1 2020.

Highbridge Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Highbridge Capital Management sold 96,060 Ionis Pharmaceuticals shares in Q1 2020, an estimated $5.8M.
Highbridge Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Highbridge Capital Management's Ionis Pharmaceuticals position peaked at $5.8M in Q4 2019.
363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2020.

Based on Highbridge Capital Management's 13F filing for Q1 2020, filed 15 May 2020.